- Primary research
- Open Access
Morphologic transformation of human breast epithelial cells MCF-10A: dependence on an oxidative microenvironment and estrogen/epidermal growth factor receptors
© Yusuf and Frenkel; licensee BioMed Central Ltd. 2010
- Received: 9 April 2010
- Accepted: 1 September 2010
- Published: 1 September 2010
MCF-10A, immortalized but non-transformed human breast epithelial cells, are widely used in research examining carcinogenesis. The studies presented here were initiated with the observation that MCF-10A cells left in continuous culture for prolonged periods without re-feeding were prone to the development of transformed foci. We hypothesized that the depletion of labile culture components led to the onset of processes culminating in the observed cell transformation. The purpose of this study was to define the factors which promoted transformation of this cell line.
Changes in levels of phenol red (PHR), hydrocortisone (HC), and epidermal growth factor (EGF) with or without estrogen treatment indicated that both oxidative stress- and estrogen receptor alpha (ERα)-mediated pathways contribute to cell transformation. Gene array and Western blotting analyses of cells maintained in our laboratory and of those from other sources documented detectable ERα and ERbeta (ERβ) in this ERα-negative cataloged cell line. Results also indicate the possibility of a direct association of EGF receptor (EGFR) and ERα in these cells as well as the formation and high induction of a novel ternary complex that includes ERβ (ERα/ERβ/EGFR) in cells grown under conditions facilitating transformation.
Our studies resulted in the development of a growth protocol where the effects of chronic, physiologically relevant alterations in the microenvironment on cellular transformation were examined. From our results, we were able to propose a model of transformation within the MCF-10A cell line in which oxidative stress, ER and EGFR play essential roles. Overall, our work indicates that the immediate microenvironment of cells exerts powerful growth cues which ultimately determine their transformation potential.
- Epidermal Growth Factor Receptor
- Epidermal Growth Factor
- Human Breast Epithelial Cell
- Epidermal Growth Factor Concentration
- Epidermal Growth Factor Receptor Antibody
Breast cancer is one of the most common malignancies affecting women in Western countries . Despite extensive research efforts worldwide at understanding and eradicating breast cancer, the cellular processes that lead to the onset of mammary carcinogenesis have yet to be definitively elucidated. Oxidative stress has come under increasing scrutiny in recent years as a causative factor in mammary carcinogenesis. Chronic infection and inflammation, which lead to reactive oxygen species (ROS) generation, are recognized risk factors for cancer development . 17β-Estradiol (E2) [3–6] and epidermal growth factor (EGF) [7, 8], two agents that can increase intracellular oxidative stress, are also strongly linked to the development of breast cancer. E2 binding to estrogen receptor (ER) [9–11] and EGF's known properties as a growth factor, [1, 12] as well as its putative role in modulating ER expression [13, 14], could also lead to cell transformation through the induction of cellular proliferative responses.
Epidemiological evidence and the recognized risk factors implicate estrogens as important etiological agents in the development of breast cancer [9, 15–20]. The exact mechanism(s) by which estrogen contributes to the development of breast cancer has not yet been elucidated. Most studies to date have focused on estrogen's role as a promoter of carcinogenesis based on its proven mitogenic activity in cells [9, 10, 21]. Receptor-based increases in cell proliferation due to estrogen binding are thought to act by either increasing spontaneous errors that make target tissues more susceptible to initiation or enhancing the replication of clones of already initiated target cells . Increasingly, however, the notion that estrogen can function as an initiator of breast cancer via ROS generation and consequent oxidative DNA damage is gaining experimental support [3–5, 21–24].
Over two decades ago, J. Liehr and coworkers elegantly demonstrated that while 17β-estradiol (E2) exposure induces renal clear-cell carcinoma in Syrian hamsters, 2-fluoroestradiol (2-Fl-E2), a fluorinated estrogen analog that is a potent estrogen but displays reduced metabolic conversion to catechol estrogen metabolites, was non-carcinogenic in this system [25, 26]. Oxidation of cytochrome P450-catalyzed catechol estrogen (CE) metabolites, particularly 4-hydroxyestradiol (4-OH-E2), to semiquinones and quinones and their redox cycling, is thought to generate free radicals which can effect oxidative DNA damage [22, 23, 27, 28] leading to mutations and carcinogenesis. 4-OH-E2 is the predominant catechol formed in human mammary fibroadenomas and adenocarcinomas tested . The localized occurrence of a specific estrogen 4-hydroxylase (CYP1B1) in human breast cancer cells, uterine myoma, and rodent target organs of estrogen-induced carcinogenesis has also been observed . Further, formation of 8-hydroxy-2'-deoxyguanosin (8-OHdG) was higher in ERα-positive cultured human breast cancer cells and tissues in comparison to ERα-negative cells . Studies conducted with human sperm and lymphocytes provided evidence that exposure to various estrogenic compounds can lead to free radical-mediated damage as well. This damage was diminished in nearly all cases by catalase, indicating that estrogen-mediated effects act via hydrogen peroxide (H2O2) production .
ERα levels can be modulated by EGF [13, 14], which was shown to increase oxidative DNA damage in mammary tumor cells coincident with increased malignancy . EGF, a growth factor regulating the proliferation and differentiation of human mammary epithelial cells, is thought to be involved in the pathophysiology of breast cancer [1, 12]. Underscoring its significance in mammary carcinogenesis, EGF is present in several human breast cancer cell lines and in 15-30% of human primary invasive breast carcinomas; its mRNA is elevated in ERα-positive human breast cancer cell lines and tumors, and its expression correlates with poor prognosis in breast cancer patients . EGF by itself can increase H2O2 levels [7, 8] and, thus, may be a critical factor in oxidative stress-induced breast cancer.
The culture medium of MCF-10A cells is usually supplemented with various factors such as hydrocortisone (HC), EGF, and phenol red (PHR, a pH indicator), which can affect redox state as well as ER activity. We observed in this study that MCF-10A cells left in continuous culture for prolonged periods without re-feeding were prone to the development of morphologically transformed foci. Our hypothesis was that the depletion of labile culture components induced oxidative stress and led to the onset of spontaneous transformation. However, deliberate manipulation of culture components and treatment with redox active and inactive estrogens indicated both oxidative stress- and ERα-mediated pathways to be operative in the spontaneous transformation of these cells. While MCF-10A cells are characterized as ERα-negative, gene array and western blotting analyses of cells maintained in our laboratory as well as of those obtained from a variety of different sources provided documentation of detectable ERα and ERbeta (ERβ) in this cell line. Western blotting analysis also indicated for the first time the possibility of a direct association of epidermal growth factor receptor (EGFR) and ERα in the MCF-10A cell line as well as the formation and high induction of a novel ternary complex that includes ERβ (ERα/ERβ/EGFR) in MCF-10A cells grown under conditions facilitating their transformation.
A. Cells and Materials
MCF-10A cells were purchased from American Type Culture Collection (ATCC; Manassas, VA). MCF-10A cells were also kindly provided by Drs. J.D. Yager (Department of Environmental Health Science, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; Source #1), K. Eckert (Gittlen Cancer Research Institute, Penn State College of Medicine, Hershey, PA; Source #2), M. Planas-Silva (Department of Pharmacology, Penn State College of Medicine, Hershey, PA; Source #3), and M. F. Verderame (Department of Medicine, Penn State College of Medicine, Hershey, PA; Source #4). The laboratories at Penn State University that kindly provided MCF-10A cells had obtained these cells independently of one another from different sources. A custom formulation of PHR-free Dulbecco's Modified Eagle's Medium/Nutrient F12 (DMEM/F12) cell culture medium D231SA, trypsin (0.25%, 1×), trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; 0.05% trypsin, 0.53 mM EDTA, 1×), L-glutamine (200 mM, 100×), and antibiotic/antimycotic (100×) solutions were purchased from Atlanta Biologicals (Norcross, GA). Horse serum (HS) was purchased from Invitrogen (Carlsbad, CA). EGF was purchased from R&D Systems (Minneapolis, MN). Protease inhibitor cocktail tablets were obtained from Roche Molecular Biochemicals (Indianapolis, IN). All other reagents were purchased as described in the text or from Sigma Chemical Company (St. Louis, MO).
B. Cell Culture
MCF-10A cells were maintained in PHR-free DMEM/F12 culture medium unless otherwise specified. Medium was supplemented with NaHCO3 (1200 mg/L), CaCl2 (1.05 mM), 5% HS, insulin (10 μg/ml), L-glutamine (2 mM), antibiotic/antimycotic mixture (1%), EGF (20 ng/ml), HC (500 ng/ml), and cholera toxin (100 ng/ml). Cells were fed twice a week and grown to confluence before subculturing. Briefly, cells were washed once with Dulbecco's Phosphate Buffered Saline (D-PBS) and exposed to trypsin for 15-20 minutes before the action of trypsin was stopped with 20% HS-supplemented medium. Cells were then centrifuged at 100 × g in a tabletop centrifuge for 5 min and the cell pellet was resuspended in medium and transferred to other flasks. All cells were grown in a single chamber water-jacketed humidified incubator and maintained in a 37°C, 5% carbon dioxide (CO2) atmosphere. The number of passages cells have been propagated in a particular type of medium is indicated in parentheses next to the description of the medium [(i.e. -HC/-EGF (#10)]
C. Assay for Morphologic Transformation
MCF-10A cells maintained in PHR-free 5% HS-supplemented, HC and EGF-containing [+HC/+EGF (+/+)] DMEM/F12 medium were subsequently grown for the 5-week morphologic transformation assay in +/+, -HC/-EGF (-/-), -HC/+EGF (-/+), or +HC/-EGF (+/-) DMEM/F12 media supplemented with 0.5% HS and 240 μg bovine serum albumin (BSA)/ml in the absence or presence of PHR. Cells in these eight medium groups were non-treated (NT) or treated with 0.01% ethanol (EtOH) alone or with 0.01% EtOH solution of 1 nM E2 or 1 nM 2-fluorestradiol (2-Fl-E2). Initially, cells were either left untreated or treated with appropriate agents and then plated in triplicate in 6-well plates at a density of 5 × 105 cells/well. Thereafter, cells were maintained in continuous culture for 6 weeks, refed and re-treated once a week, and examined microscopically each week for signs of contact-uninhibited growth and the appearance of morphologically transformed foci. Transformed foci were counted once a week from 1-5 weeks at 4× magnification as they appeared along two perpendicular lines intersecting in the center of each well. To assess the reversibility of phenotypic cell alterations, after five weeks, PHR, HC, and EGF were added back singly or together, to cultures that were lacking these factors, and the number of transformed foci was again determined at week 6. The assay was performed once with duplicates of each treatment analyzed. Some treated cells were plated in poly-D-lysine-coated tissue-culture plates in an attempt to increase detailed microscopic visualization and examination of foci.
D. Western Immunoblotting Analysis
Cells used for Western blot analysis included MCF-10A cells (non-treated and treated under various treatment protocols and media conditions) as well as MCF-10A cells acquired from different laboratories and grown in -PHR, 5% HS, +/+ medium. Total cell extracts were obtained by first trypsinizing and pelleting cells as described in section B of Materials and Methods and washing once with D-PBS. Cell lysis buffer [5.0 M EDTA, 150 mM NaCl, 50 mM Tris HCl, 1% Triton X-100, 1% SDS, 50 mM dithiothreitol (DTT), and protease inhibitor cocktail tablets (1 tablet per 10 ml buffer)] was added to each tube at 100 μl buffer per 1 × 106 cells and mixed well to lyse the cells completely. Lysates were transferred to microcentrifuge tubes, incubated on ice for 10-30 min., and centrifuged at 12,000 × g in a microcentrifuge at 4°C for 15 min. The supernatants were collected and stored at -80°C for subsequent analyses. Alternately, Pierce (Rockford, IL) NE-PER Nuclear and Cytoplasmic Extraction Reagents were used as per the manufacturer's protocol for the stepwise separation and preparation of cytoplasmic and nuclear extracts. Protein content was measured using Bradford Reagent. Proteins (25-30 μg) were resolved by SDS-PAGE in 12% SDS-Tris-HCl polyacrylamide mini-running gels and transferred onto nitrocellulose membranes (BioRad Laboratories; Hercules, CA). Membranes were incubated with primary antibodies to ERα, ERβ, or EGFR at a dilution of 1:1000 in 5% non-fat dry milk-Tris Buffered Saline/Tween (TBS/T) buffer at 4°C overnight, followed by incubation with both the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody at a dilution of 1:10,000 and anti-biotin antibody at 1:1000 dilution in 5% non-fat dry milk in TBS/T at room temperature (RT) for 1 h. Protein was detected using the Western Lightning Chemiluminescent Reagent Plus Kit from PerkinElmer (Wellesley, MA) as per the manufacturer's directions. Antibodies (Ab) and controls used were: ERα (62A3) mouse monoclonal Ab, EGFR rabbit polyclonal Ab, and anti-biotin Ab (Cell Signaling Technology; Beverly, MA); ERβ (PA1-313) rabbit Ab, human, recombinant ERα RP-310 and ERβ (long form) RP-312 (Affinity BioReagents; Golden, CO); EGF-stimulated A431 cell lysate (Upstate Biotechnology; Lake Placid, NY). Peroxidase-conjugated Immunopure goat anti-mouse and sheep anti-rabbit IgG's were used as secondary antibodies (Pierce Chemical Company, Rockford, IL)
E. Gene Expression Analysis of the Human Toxicity/Stress and Estrogen Signaling Pathways
Cells were trypsinized and pelleted according to the protocol outlined in Section B, and RNA was isolated from cells using the RNAqueous RNA isolation system (Ambion, Inc.; Austin, TX) according to the manufacturer's protocol. Immediately afterwards, contaminating DNA was removed using Ambion's "DNA-free" DNase Treatment and Removal Reagents again as per the manufacturer's directions. The RNA supernatants were transferred to new RNAse-free tubes and stored at -80°C. Prior to use in gene expression studies, the concentration and purity of RNA was determined by aliquoting a small amount of the samples in HPLC-grade, RNase-free dH2O and measuring absorbance at 260 nm and 280 nm. RNA concentration was calculated using a value of 1A260 nm = 40 μg RNA/ml. and its purity assessed by confirming that the ratio of A260/A280 was near 2.0. Nonrad-GEArray Kit Pathway Specific Gene Expression Profiling System (SuperArray, Inc; Bethesda, MD) was used for the analysis of gene expression after RNA isolation. The detailed manufacturer's protocol was followed for analysis. Briefly, biotinylated cDNA probes were synthesized from 5-10 μg total RNA by reverse transcription using a PCR thermal cycler and SuperArray reagents. Afterwards, cDNA probes were hybridized using a mini hybridization incubator kit reagents to pathway-specific gene expression array membranes (either human toxicity/stress or estrogen signaling) provided by the manufacturer. Finally, membranes were incubated with alkaline phosphatase (AP)-streptavidin, and chemiluminescent detection was performed with the provided CDP-Star substrate and immediate exposure to x-ray film between 0-5 min. Signal intensities were quantitated (semi-log) using UN-SCAN-IT digitizing software (Silk Scientific; Orem, UT) after the x-ray films were scanned onto a computer. Sample signal intensities were normalized against a housekeeping gene's signal intensities. Each membrane contained two spots for each cDNA analyzed. Means of the intensity (in pixels) of the duplicate spots were used for analysis
F. Statistical Analysis
Significance of differences between two groups was assessed using one-tailed Student's "t" test assuming unequal variances. One-way ANOVA followed by Dunnet's test was utilized to compare all groups to a control group, while One-way ANOVA followed by Tukey's test was used to compare all groups to each other. For all tests, p < 0.05 was considered significant.
1. Simultaneous depletion of HC, EGF, and PHR from culture medium is necessary for the morphologic transformation of MCF-10A cells
Effects of PHR, HC, EGF, E2, and 2-Fl-E2 on the Appearance of Transformed Foci in MCF-10A Cells after 5 Weeks in Continuous Culture
Number of Foci/Well
(+HC/+EGF) -PHR; 1 nM E2
79.50 +/- 6.50*, #
(-HC/-EGF) -PHR; 0.01% EtOH
33.50 +/- 27.50
(-HC/-EGF) -PHR; 1 nM E2
182.00 +/- 2.00**,Φ
(-HC/-EGF) -PHR; 1 nM 2-Fl-E2
19.00 +/- 5.00*
(-HC/+EGF) -PHR; 1 nM E2
(+HC/-EGF) -PHR; 1 nM E2
2. β-Estradiol (E2) elevates the morphologic transformation of MCF-10A cells in -HC/-EGF (-/-) medium, whereas 2-Fl-E2 does not
3. Re-introduction of HC, but not PHR or EGF, to -PHR/-HC/-EGF MCF-10A cultures after 5 weeks can partially reverse morphologic transformation
Reversibility of Morphologic Transformation due to Re-addition of PHR, HC, and/or EGF to MCF-10A Cells Grown for 5 Weeks in -PHR/-HC/-EGF Medium
Mean Number of Foci/Well +/- SE
153.50 +/- 0.50
Add Back PHR
157.50 +/- 4.50
125.67 +/- 4.98
Add Back HC
75.33 +/- 6.74*
79.50 +/- 6.50
Add Back EGF
92.50 +/- 12.50
145.50 +/- 12.00
Add Back HC & EGF
156.50 +/- 12.50
4. MCF-10A transformed foci exhibit extensive interconnections while displaying varying morphologies depending on the growth condition
5. MCF-10A cells exhibit detectable levels of both ERα and ERβ gene expression
Estrogen Receptor Gene Expression in MCF-10A Cells Under Various Treatment and Culture Conditions
ERα (Mean Gene Expression)
ERβ (Mean Gene Expression)
-HC/+EGF (#21); NT
-HC/-EGF (#1); 1 nM E2
-HC/-EGF (#1); NT
-HC/-EGF (#1); 1 nM E2
6. Western blotting confirms the presence of ERα and ERβ in MCF-10A cells; Possibility of a direct association of ERα and EGFR, with induction of a putative ternary complex composed of ERα/ERβ/EGFR in those cells that are the most prone to transformation
7. Modulation of ER-responsive genes in MCF-10A cells by E2 and redox manipulation
Comparison of Progesterone Receptor and Prolactin Gene Expression in 1 nM E2-Treated versus Non-treated MCF-10A -HC/-EGF (#1) Cells
Gene Expression in
-HC/-EGF (#1) Cells
Gene Expression in
-HC/-EGF (#1) Cells
(1 nM E2)
Comparison of Estrogen Signaling Pathway Gene Expression in MCF-10A - HC/+EGF (#21) versus +HC/+EGF Cells
Mean Gene Expression in
Mean Gene Expression in
22.50 +/- 4.70
12.36 +/- 3.37
11.87 +/- 2.78
3.83 +/- 2.20
2.20 +/- 0.03
0.00 +/- 0.00**
8.11 +/- 3.2
1.82 +/- 0.79
8.05 +/- 2.98
2.08 +/- 0.25
6.75 +/- 1.35
1.95 +/- 1.85
32.19 +/- 2.42
8.57 +/- 0.16*
1.16 +/- 0.91
3.73 +/- 1.84
The mandatory depletion of HC, a potent anti-inflammatory agent thought to decrease oxidative stress in cells, in order to transform cells suggests that an oxidant milieu is critical to the carcinogenic process (Figs. 1 & 2). However, re-addition of HC, significantly (p < 0.01), but only partially, reversed the morphologic transformation seen in 5-week -/- MCF-10A continuous cultures (Table 2). The inhibitory effect of added HC on cell transformation and the reversible nature of its action have been documented in various cell types [36–38]. For example, the presence of HC reversibly mediated growth inhibition as well as anchorage-dependence of rat C6 glioma cells and blocked colony formation in agarose [36, 37]. HC-mediated ROS suppression [39, 40], decrease of nuclear NF-κB , and increases in antioxidant enzymes  are likely responsible for such transformation-retarding effects.
Transformation of MCF-10A cells, however, was also dependent on the simultaneous depletion of EGF from the culture medium (Figs. 1 & 2); hence, EGF withdrawal-mediated ROS generation could play a role in such transformation. In mouse proximal tubular (MPT) cells, EGF deprivation was shown to elevate cellular superoxide anion radical levels and induce apoptosis . However, by itself, EGF can trigger H2O2 production [7, 8] and thus, the finding that its presence inhibits transformation supports the possible outgrowth of EGF-independent clones and suppression of EGFR activity as important events in the transformation pathway [44, 45] as well. In fact, adding back EGF, both by itself or with HC resulted in a slight increase in the number of foci (Table 2) and points to the possible outgrowth of EGF-autonomous cells, which then become hypersensitive to the action of EGF perhaps due to the acquisition of a constitutively active EGFR pathway. Lack of EGF in cell culture medium has previously been linked to the spontaneous transformation of HMT-3522 cells [46, 47], to carcinogen-initiated neoplastic transformation of Syrian golden hamster pancreatic duct cells , and to benzo[a]-pyrene (BP)-enhanced cell proliferation in MCF-10A cells .
Our studies showed that transformation rates of MCF-10A cells treated with 1 nM E2 were elevated by over 5-fold in comparison to those of EtOH controls, only within a pre-existing oxidant microenvironment generated by HC and, possibly, EGF depletion (Table 1). The probability that E2-mediated transformation relies on the generation of ROS is indicated by the observation that 1 nM 2-Fl-E2, an estrogen whose metabolism leads to the formation of lower levels of oxidants [4, 25–27, 50], is incapable of increasing transformation in MCF-10A cells over EtOH controls (Table 1). Studies previously conducted in animals and in various cell models implicate estrogens in transformation, ROS generation, and oxidative DNA damage, particularly 8-OHdG [25, 28, 30–32, 51, 52]. Yet, our data also implicated estrogen receptor-mediated effects on cellular transformation. MCF-10A cells exposed to E2 are refractory to transformation even in the absence of HC (-/+ cultures) but in the presence of EGF (Figs. 1 & 2; Table 1), implying a need for the possible upregulation of ER-α, due to EGF withdrawal, within the carcinogenic process in this model. Low EGF concentrations in a low serum-containing medium stimulated growth of high ERα-expressing human breast cancer cell lines A431 and BT20, while high EGF doses inhibited their growth . Taken together, the data implicate EGF independence and E2-generated ROS and/or ERα-mediated events as possible contributors to MCF-10A transformation.
The presence of ERα in this ERα-negative categorized cell line and its importance in transformation is underscored by observed transformation suppression in the presence of PHR (Figure 3; Table 1) at 5 days (data not shown), 13 days (Fig. 1), and 5 weeks (Fig. 2). PHR, a known weak estrogen [32, 33] used as a pH indicator at a concentration of 15-45 μM in most tissue culture media, can bind to the ERα of MCF-7 human breast cancer cells at an affinity of 0.001% of E2 and was seen to reduce ERα-mediated growth stimulatory processes of exogenous estrogens . The PHR concentration of media used in the present study (21.5 μM) could, therefore, effectively have blocked E2-mediated hormonal and/or oxidative effects on foci formation, as was observed. MCF-10A cells are normally cultured in medium supplemented with horse serum (HS), which contains estradiol. It is possible that chronic exposure of MCF-10A cells to picomolar (~6 × 10-12 M) estradiol contained in HS led to upregulated ERα expression and contributed in part to the transformation of MCF-10A cells seen in -/- medium even in the absence of added E2 (NT and ethanol controls). We found that ERα-mediated events in MCF-10A cell transformation most likely constitute irreversible alterations since re-introducing PHR to culture medium had no effect on the number of foci, once formed (Table 2).
Gene expression arrays confirmed the expression of both ERα and ERβ in MCF-10A cells (Table 3) as well as estrogen responsive genes (Tables 4 & 5). The persistent, detectable levels of ERα and ERβ observed among varying culture conditions and treatments (Table 3), even in cells newly purchased from ATCC, provide evidence contradicting the classification of the MCF-10A cell line as ERα-negative. Hormonal estrogen responsiveness was also indicated by the observation that a 1 nM E2 treatment of -/- MCF-10A cultures upregulated prolactin (PRL) gene expression by > 6-fold, while it down-regulated progesterone receptor (PR) gene expression by >2-fold (Table 4). Such modulation has important implications for mammary cell differentiation/proliferation and cancer development. Pituitary prolactin levels are known to be increased due to exposure to exogenous estrogens , promote mammary cancer in rats and mice  and can activate Ras in rat lymphoma cells  with recent studies linking circulating levels to breast cancer . PR, as well, is known to induce mammary epithelial cell proliferation [58, 59] and contribute to mammary tumorigenesis . Similar to our findings, suppression of PR gene expression in human breast epithelial cells ML-20 and KPL-1 within a hypoxic microenvironment promoted malignancy . Interestingly, we noted that HC withdrawal was noted to modulate expression of estrogen responsive genes pS2, EBAG9, and PRL and genes involved in estrogen signaling such as EGF, c-fos, c-jun, c-myc, and H-ras (Table 5), which may be the result of an attempt by the cell to combat oxidative stress-induced cellular transformation.
The reasons for down-regulated EGF expression due to HC withdrawal are unclear. However, the presence of EGF inhibited MCF-10A foci formation even when cells were continuously treated with E2 (Table 1). EGF withdrawal was previously documented to transform human breast epithelial cell line HMT-3522, where EGFR suppression was posited to promote estrogen-responsive breast cancer [44, 45]. As well, low EGF levels present in low serum-containing medium stimulated growth of human breast cancer cell lines A431 and BT20, expressing high ERα levels, while high EGF concentrations inhibited cell growth . Interestingly, in EGF-depleted MCF-10A cells, increased ROS generation due to benzo[a]pyrene-quinone (BPQ) exposure was seen to activate EGFR . In other studies, redox regulation of ER was also apparent, where H2O2-induced oxidative stress in MCF-7 and T-47 D human breast cancer cells led to a minimal upregulation of ER-α but a significant increase in ER-β levels . The initial depletion of HC and EGF from the growth medium of MCF-10A cells could lead to the upregulation of ER expression due to both EGF withdrawal-mediated effects and elevated oxidative stress. At the same time, increased oxidant levels concomitant with EGF-withdrawal may also activate EGFR in these cells. EGF hypersensitivity was already noted in our system (Table 2).
Further support for increased ER and EGFR activities due to increased oxidative stress and concomitant EGF withdrawal was provided by the possible existence of a novel, yet still highly speculative, direct association of EGFR and ERα in MCF-10A seen to be induced and believed to include the presence of ERβ in chronic HC/EGF-depleted MCF-10A cells (Fig. 7), which are the most prone to transformation. A puzzling observation in the Western blots showing this ternary complex formation is the presence of the ~200 kD band in lanes containing the recombinant proteins ERα and ERβ synthesized in baculovirus-infected Sf9 cells (Fig. 7a-b; lanes 1 & 9 and Fig. 7c-d; lanes 2 & 10). This observation can only be explained by copurification of these recombinant proteins with contaminating host EGFR proteins. Yet, Sf9 are insect spodoptera frugiperda cells do not contain human EGFR. However, Sf9 cells do contain a growth-blocking peptide receptor (GBPR) having a tyrosine phosphorylation subunit, which can bind human EGF, and can be detected in gels by probing with anti-human EGFR antibody . Thus, association of GBPR with ERα or ERβ during their synthesis in Sf9 cells would explain the presence of the ~200 kD band in bands containing the recombinant proteins and probed with their respective antibodies. Detection of the ~200 kD band in lanes containing both recombinant ERα and ERβ indicate that GBPR can associate with both proteins, yet these bands would not cross-react with both ERα and ERβ antibodies, as seen, since only one protein would be synthesized at a time in Sf9 cells. The absence of a ~200 kD band in lanes containing recombinant ERα or ERβ in gels probed with EGFR antibodies (Fig. 7e-f; lanes 1-2 & 9-10) may be due to the fact that the EGFR moiety detected by the particular EGFR antibody used is not present in GBPR.
Induction of this, as yet speculative, ERα/ERβ/EGFR ternary complex formation may provide an explanation and plausible mechanism for the increased EGF and E2 sensitivity noted in the transformation of this cell line. Chronic withdrawal of HC/EGF from MCF-10A cell cultures seems to strongly facilitate the formation of this putative ERα/ERβ/EGFR ternary complex, a possible manifestation of the ER and EGFR upregulation induced by increased ROS and EGF deficiency in the microenvironment, thereby conferring both EGF and E2 hypersensitivity to cells. While work by other laboratories have implicated either ER or EGFR upregulation/activation due to the actions of EGF withdrawal and increased oxidative stress either by themselves or together, the present study indicates increased activation of both ER and EGFR in the MCF-10A cell line due to the simultaneous effects of both increased oxidant stress and EGF withdrawal. The transformation-enhancing action of such EGF and E2 hypersensitivity can be mediated by the induction of this possible ERα/ERβ/EGFR ternary complex noted to occur under EGF-deficient, pro-oxidant conditions. Marquez et al. have also demonstrated a novel direct interaction between ER and EGFR after EGF treatment of MCF-7 cells where EGFR tyrosine kinase phosphorylates ERα at tyrosine-537 and tyrosine-43, possibly leading to estrogen-independent activation of ER-mediated transcription and cell proliferation [63, 64]. Others have reported similar results . Proteins recognized by ER-α and ER-β monoclonal antibodies were found in close association to EGFR in lung tumor cells . As well, estrogen was seen to promote an association between extranuclear ER-α and the EGFR family member ERBB4 in the T47 D breast cancer cell line . Such cross-talk can activate diverse downstream signal transduction pathways which regulate cell proliferation [66, 68]. In addition, bi-directional cross talk between ER and EGFR can enhance the individual actions of steroids . Thus, augmented cell proliferation and survival responses [14, 63, 70–72] due to ER/EGFR interactions in MCF-10A cells can possibly lead to their transformation. Several laboratories have posited the probable co-existence and/or necessity for ER-mediated proliferative effects and CE-mediated genotoxic and oxidative events in carcinogenic process [20, 73, 74]. Results from the present study indicate this to be the case in the transformation of MCF-10A cells.
Part of the cellular machinery enabling such transformation is suggested by the unique cellular interconnections we observed within cultures grown in media conducive to transformation (Figs. 5 & 6). While the exact function of these interconnections is unknown, it is possible that they facilitate the channeling and/or sharing of nutrients, growth factors, etc., needed for foci survival. The discovery of the de novo creation of actin-based tunneling nanotubules (TNTs) which arise due to medium deprivation and are capable of transporting organelles between cells in different cells  provides support for this type intercellular communication.
This study demonstrates that microenvironmental manipulations, namely the simultaneous depletion of HC and EGF from culture medium, which increase intracellular oxidative stress, can induce transformation in the MCF-10A cell line. We have developed a growth protocol in which the effect of chronic, physiologically relevant microenvironmental alterations on cellular transformation can be examined. Each analysis of duplicate or triplicate samples from single experiments presented in this study represents the culmination of extensive prior work in the selection of optimal culture and treatment conditions. Exposure of cells to chronic, physiologic doses of E2 were required to effect transformation, conditions that mimic the lifetime exposure of the human breast to endogenous estrogens which is believed to play a part in the onset of breast cancer [76, 77]. Both E2-mediated oxidative effects and ER-mediated events were found necessary to effect transformation. Our work provides the first indications suggesting a direct association of EGFR and ERα as well as a possible ternary association (ERα/ERβ/EGFR), which is highly induced in chronically HC/EGF-depleted MCF-10A cells which are the most prone to transformation. Overall, results indicate that the immediate microenvironment of cells exerts powerful growth cues which ultimately determine their transformation potential.
This study was supported in part by grants from National Cancer Institute (CA37858), National Institute on Aging (AG14587), and Environmental Health Sciences (ES00260). The Authors are particularly grateful to Dr. Joachim Liehr's laboratory for providing 2-Fl-E2. We dedicate this paper to Dr. Joachim Liehr, whose prior work helped steer the thinking and experimental design for the present study.
- Gullick JW, Bianco C, Normanno N, Martinez-Lacacia I, De Santis M, Ebert AD, Salomon DS: Growth factors and their receptors: a novel approach to the endocrinology of human breast cancer. Women and Cancer. 1998, 1: 29-57.Google Scholar
- Ohshima H, Bartsche H: Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation Res. 1994, 305: 253-256.View ArticlePubMedGoogle Scholar
- Li Y, Trush MA, Yager JD: DNA damage caused by reactive oxygen species originating from a copper-dependent oxidation of the 2-hydroxy catechol of estradiol. Carcinogenesis. 1994, 15: 1421-1427. 10.1093/carcin/15.7.1421.View ArticlePubMedGoogle Scholar
- Yager JD: Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst. 2000, 27: 67-73.View ArticleGoogle Scholar
- Hayashi N, Hasegawa K, Komine A, Tanaka Y, McLachlan JA, Barrett JC, Tsutsui T: Estrogen-induced cell transformation and DNA adduct formation in cultured Syrian hamster embryo cells. Mol Carcinogenesis. 1996, 16: 149-156. 10.1002/(SICI)1098-2744(199607)16:3<149::AID-MC5>3.0.CO;2-C.View ArticleGoogle Scholar
- Bolton JL, Thatcher GRJ: Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol. 2008, 21 (1): 93-101. 10.1021/tx700191p.PubMed CentralView ArticlePubMedGoogle Scholar
- Hamada J, Nakata D, Nakae D, Kobayashi Y, Akai H, Konishi Y, Okada F, Shibata T, Hosokawa M, Moriuchi T: Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation. J Natl Cancer Inst. 2001, 93: 214-219. 10.1093/jnci/93.3.214.View ArticlePubMedGoogle Scholar
- Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, Lambeth JD: Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci. 2001, 98: 5550-5555. 10.1073/pnas.101505898.PubMed CentralView ArticlePubMedGoogle Scholar
- Fishman J, Osborne MP, Telang NT: The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci. 1995, 768: 91-100. 10.1111/j.1749-6632.1995.tb12113.x.View ArticlePubMedGoogle Scholar
- Dickson RB, Stancel GM: Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst. 2000, 27: 135-145,.View ArticleGoogle Scholar
- Tsutsui T, Barrett CJ: Neoplastic transformation of cultured mammalian cells by estrogens and estrogen-like chemicals. Environ Health Perspect Suppl. 1997, 105: 619-624. 10.2307/3433380.View ArticleGoogle Scholar
- Normanno N, Ciardiello F: EGF-related peptides in the pathophysiology of the mammary gland. J. Mammary Gland Biol. Neoplasia. 1997, 2: 143-151.Google Scholar
- Cormier EM, Wolf MF, Jordan VC: Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res. 1989, 49 (3): 576-580.PubMedGoogle Scholar
- Stoica A, Saceda M, Doraiswamy VL, Coleman C: Regulation of estrogen receptor-α gene expression by epidermal growth factor. J Endocrinol. 2000, 165 (2): 371-378. 10.1677/joe.0.1650371.View ArticlePubMedGoogle Scholar
- Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med. 2001, 344: 276-285. 10.1056/NEJM200101253440407.View ArticlePubMedGoogle Scholar
- Fuqua SAW, Russo J, Shackney SE, Stearns ME: Estrogen, estrogen receptors and selective estrogen receptor modulators in human breast cancer. Women and Cancer. 2000, 2: 21-32.Google Scholar
- Khan SA, Sachdeva A, Naim S, Meguid MM, Marx W, Simon H, Halverson JD, Numann PJ: The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. Cancer Epidemiol. Biomarkers & Prev. 1999, 8: 867-872.Google Scholar
- Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MPA, Sibson DR, Sloane JP: Estrogen receptor-positive proliferating cells in the normal and pre-cancerous breast. Amer J Pathol. 1999, 155: 1811-1815.View ArticleGoogle Scholar
- Cavalieri E, Rogan E: The unifying mechanism in the initiation and prevention of breast and other cancers. BMC Proceedings. 2009, 3 (Suppl 5): S8-10.1186/1753-6561-3-s5-s8.PubMed CentralView ArticleGoogle Scholar
- Russo J, Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006, 102: 89-96,. 10.1016/j.jsbmb.2006.09.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Russo IH, Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998, 3: 49-61. 10.1023/A:1018770218022.View ArticlePubMedGoogle Scholar
- Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T: Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006, 1766: 63-78.PubMedGoogle Scholar
- Fernandez SV, Russo IH, Russo J: Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer. 2006, 118: 1862-1868. 10.1002/ijc.21590.View ArticlePubMedGoogle Scholar
- Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, Hei TK, Bhat H: Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol. 2008, 232 (1): 78-85. 10.1016/j.taap.2008.06.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Liehr JG: 2-Fluoroestradiol, separation of estrogenicity from carcinogenicity. Mol Pharmacol. 1983, 23 (2): 278-281.PubMedGoogle Scholar
- Liehr JG, Stancel GM, Chorich LP, Bousfield GR, Ulubelen AA: Hormonal carcinogenesis: separation of estrogenicity from carcinogenicity. Chem Biol Interact. 1986, 59 (2): 173-184. 10.1016/S0009-2797(86)80064-3.View ArticlePubMedGoogle Scholar
- Liehr JG: Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev. 1997, 6: 3-10. 10.1097/00008469-199702000-00002.View ArticlePubMedGoogle Scholar
- Han X, Liehr JG: 8-hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. Cancer Res. 1994, 54: 5515-5517.PubMedGoogle Scholar
- Liehr JG, Ricci MJ: 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci. 1996, 93: 3294-3296. 10.1073/pnas.93.8.3294.PubMed CentralView ArticlePubMedGoogle Scholar
- Musarrat J, Arezina-Wilson J, Wani AA: Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer. 1996, 32A: 1209-1214. 10.1016/0959-8049(96)00031-7.View ArticlePubMedGoogle Scholar
- Anderson D, Schmid TE, Baumgartner A, Cemeli-Carratala E, Brinkworth MH, Wood JM: Oestrogenic compounds and oxidative stress (in human sperm and lymphocytes in the Comet assay). Mutat Res. 2003, 544: 173-178. 10.1016/j.mrrev.2003.06.016.View ArticlePubMedGoogle Scholar
- Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA. 1986, 83 (8): 2496-2500. 10.1073/pnas.83.8.2496.PubMed CentralView ArticlePubMedGoogle Scholar
- Rajendran KG, Lopez T, Parikh I: Estrogenic effect of phenol red in MCF-7 cells is achieved through activation of estrogen receptor by interacting with a site distinct from the steroid binding site. Biochem Biophys Res Commun. 1987, 142 (3): 724-731. 10.1016/0006-291X(87)91474-4.View ArticlePubMedGoogle Scholar
- Grenman SE, Van Dyke DL, Worsham MJ, England B, McClatchey KD, Hopkins M, Babu VR, Grenman R, Carey TE: Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B. Int J Cancer. 1990, 45 (5): 920-927. 10.1002/ijc.2910450524.View ArticlePubMedGoogle Scholar
- El-Zarruk AA, van den Berg HW: The antiproliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett. 1999, 142: 185-193. 10.1016/S0304-3835(99)00167-6.View ArticlePubMedGoogle Scholar
- Armelin MCS, Stocco RC, Armelin HA: Control of rat C6 glioma cell proliferation: uncoupling of the inhibitory effects of hydrocortisone hormone in suspension and monolayer cultures. J Cell Biol. 2004, 97: 455-458. 10.1083/jcb.97.2.455.View ArticleGoogle Scholar
- Valentini SR, Oliveira ML, Sasahara RM, Armelin MC: Glucocorticoid-regulated gene in transformed to normal phenotypic reversion. Braz J Med Biol Res. 1994, 27 (2): 541-546.PubMedGoogle Scholar
- Stanulis-Praeger BM, Jacobus CH, Nuttall AE: Hydrocortisone modulates RA-induced growth inhibition of normal and transformed human embryonic lung fibroblasts. Nutr Cancer. 1986, 8 (3): 171-184. 10.1080/01635588609513891.View ArticlePubMedGoogle Scholar
- Dandona P, Thusu K, Hafeez R, Abdel-Rahman E, Chaudhuri A: Effect of hydrocortisone on oxygen free radical generation by mononuclear cells. Metabolism. 1998, 47 (7): 788-791. 10.1016/S0026-0495(98)90113-5.View ArticlePubMedGoogle Scholar
- Marumo T, Schini-Kerth VB, Brandes RP, Busse R: Glucocorticoids inhibit superoxide anion production and p22 phox mRNA expression in human aortic smooth muscle cells. Hypertension. 1998, 32: 1083-1088.View ArticlePubMedGoogle Scholar
- Dandona P, Aljada A, Ghanim H, Mohanty P, Hamouda W, Al-Haddad W: Acute suppressive effect of hydrocortisone on p47phox subunit of nicotinamide adenine dinucleotide phosphate oxidase. Metabolism. 2001, 50 (5): 548-552. 10.1053/meta.2001.22511.View ArticlePubMedGoogle Scholar
- Okada Y, Okada M: Effect of a radical scavenger "water soluble protein" from broad beans (Vicia faba) on antioxidant enzyme activity in cellular aging. J Nutr Sci Vitaminol (Tokyo). 2000, 46 (1): 1-16.View ArticleGoogle Scholar
- Lieberthal W, Triaca V, Koh JS, Pagano PJ, Levine JS: Role of superoxide in apoptosis induced by growth factor withdrawal. Am J Physiol. 1998, 275 (Renal Physiol 44): F691-F702.PubMedGoogle Scholar
- Briand P, Nielsen KV, Madsen MW, Petersen OW: Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res. 1996, 56: 2039-2044.PubMedGoogle Scholar
- Briand P, Lykkesfeldt AE: An in vitro model of human breast carcinogenesis: epigenetic aspects. Breast Cancer Res Treat. 2001, 65: 179-187. 10.1023/A:1006434503061.View ArticlePubMedGoogle Scholar
- Manni A, Wechter R, Verderame MF, Mauger D: Cooperativity between the polyamine pathway and HER-2neu in transformation of human mammary epithelial cells in culture: role of the MAPK pathway. Int J Cancer. 1998, 76: 563-570. 10.1002/(SICI)1097-0215(19980518)76:4<563::AID-IJC20>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Russo J, Calaf G, Sohi N, Tahin Q, Zhang PL, Alvarado ME, Estrada S, Russo IH: Critical steps in breast carcinogenesis. Ann New York Acad Sci. 1993, 698: 1-20. 10.1111/j.1749-6632.1993.tb17187.x.View ArticleGoogle Scholar
- Mangold KA, Hubchak S, Mangino MM, Laconi S, Scarpelli DG: In vitro carcinogenesis of hamster pancreatic duct cells: cellular and molecular alterations. Carcinogenesis. 1994, 15 (9): 1979-1984. 10.1093/carcin/15.9.1979.View ArticlePubMedGoogle Scholar
- Burdick AD, Davis II JW, Liu KJ, Hudson LG, Shi H, Monske ML, Burchiel SW: Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Cancer Res. 2003, 63: 7825-7833.PubMedGoogle Scholar
- Stalford AC, Maggs JL, Gilchrist TL, Park BK: Catecholestrogens as mediators of carcinogenesis: correlation of aromatic hydroxylation of estradiol and its fluorinated analogs with tumor induction in Syrian hamsters. Mol Pharmacol. 1994, 45 (6): 1259-1267.PubMedGoogle Scholar
- Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D: Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J Natl Cancer Inst. 2000, 27: 75-93.View ArticleGoogle Scholar
- Tritscher AM, Seacat AM, Yager JD, Groopman JD, Miller BD, Bell D, Sutter TR, Lucier GW: Increased oxidative DNA damage in livers of 2,3,7,8-tetrachlorodibenzo-p-dioxin treated intact but not ovariectomized rats. Cancer Lett. 1996, 98: 219-225.View ArticlePubMedGoogle Scholar
- Dong XF, Berthois Y, Martin PM: Effect of epidermal growth factor on the proliferation of human epithelial cancer cell lines: correlation with the level of occupied EGF receptor. Anticancer Res. 1991, 11 (2): 737-743.PubMedGoogle Scholar
- Vorherr H: Pregnancy and lactation in relation to breast cancer risk. Semin Perinatol. 1979, 3 (3): 299-311.PubMedGoogle Scholar
- Lipsett MB: Hormones, medication, and cancer. Cancer. 1983, 51 (12 Suppl): 2426-2429. 10.1002/1097-0142(19830615)51:12+<2426::AID-CNCR2820511307>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- Erwin RA, Kirken RA, Malabarba MG, Farrar WL, Rui H: Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology. 1995, 136 (8): 3512-3518,. 10.1210/en.136.8.3512.PubMedGoogle Scholar
- Arendt LM, Grafwallner-Huseth TL, Schuler LA: Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERα expression. Am J Pathol. 2009, 174 (3): 1065-1074. 10.2353/ajpath.2009.080719.PubMed CentralView ArticlePubMedGoogle Scholar
- Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW: Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999, 59 (17): 4276-4284.PubMedGoogle Scholar
- Anderson E: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002, 4: 197-201. 10.1186/bcr452.PubMed CentralView ArticlePubMedGoogle Scholar
- Kurebayashi J, Otsuki T, Moriya T, Sonoo H: Hypoxia reduces responsiveness of human breast cancer cells. Jpn J Cancer Res. 2001, 92 (10): 1093-1101.View ArticlePubMedGoogle Scholar
- Tamir S, Izrael S, Vaya J: The effect of oxidative stress on ERα and ERβ expression. J Steroid Biochem Mol Biol. 2002, 81: 327-332. 10.1016/S0960-0760(02)00115-2.View ArticlePubMedGoogle Scholar
- Ohnishi A, Oda Y, Hayakawa Y: Characterization of receptors of insect cytokine, growth-blocking peptide, in human keratinocyte and insect Sf9 cells. J Biol Chem. 2001, 276 (41): 37974-37979.PubMedGoogle Scholar
- Pietras RJ: Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J. 2003, 9 (5): 361-373. 10.1046/j.1524-4741.2003.09510.x.View ArticlePubMedGoogle Scholar
- Marquez DC, Lee J, Lin T, Pietras RJ: Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine. 2001, 16 (2): 73-81. 10.1385/ENDO:16:2:073.View ArticlePubMedGoogle Scholar
- Banerjee S, Sengupta K, Saxena NK, Dhar K, Banerjee SK: Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-α positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res. 2005, 3 (3): 151-162. 10.1158/1541-7786.MCR-04-0130.View ArticlePubMedGoogle Scholar
- Pietras R, Marquez DC, Chen H, Tsai E, Weinberg O, Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 2005, 70: 372-381. 10.1016/j.steroids.2005.02.017.View ArticlePubMedGoogle Scholar
- Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE: Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res. 2006, 66 (16): 7991-7998. 10.1158/0008-5472.CAN-05-4397.View ArticlePubMedGoogle Scholar
- Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA: Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol. 2005, 19 (11): 2660-2670. 10.1210/me.2004-0439.View ArticlePubMedGoogle Scholar
- Levin ER: Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 2003, 17 (3): 309-317. 10.1210/me.2002-0368.View ArticlePubMedGoogle Scholar
- Razandi M, Pedram A, Park ST, Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003, 278 (4): 2701-2712. 10.1074/jbc.M205692200.View ArticlePubMedGoogle Scholar
- Filardo EJ: Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002, 80: 231-238. 10.1016/S0960-0760(01)00190-X.View ArticlePubMedGoogle Scholar
- Lichtner RB: Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother. 2003, 57: 447-451. 10.1016/j.biopha.2003.09.006.View ArticlePubMedGoogle Scholar
- Hiraku Y, Yamashita N, Nishiguchi M, Kawanishi S: Catechol estrogens induce oxidative DNA damage and estradiol enhances proliferation. Int J Cancer. 2001, 92: 333-337. 10.1002/ijc.1193.View ArticlePubMedGoogle Scholar
- Russo J, Lareef MH, Balogh G, Guo S, Russo IH: Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol. 2003, 87: 1-25,. 10.1016/S0960-0760(03)00390-X.View ArticlePubMedGoogle Scholar
- Rustom A, Saffrich R, Markovic I, Walther P, Gerdes H: Nanotubular highways for intercellular organelle transport. Science. 2004, 303: 1007-1010. 10.1126/science.1093133.View ArticlePubMedGoogle Scholar
- Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR: Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol. 2001, 19 (12): 3111-3116.PubMedGoogle Scholar
- Clamp A, Danson S, Clemons M: Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol. 2002, 3 (10): 611-619. 10.1016/S1470-2045(02)00875-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.